Vir Biotechnology
VIR
8.39
-0.48
-5.41%
Vir Biotechnology
US · VIR
#2824 by market cap
Listed 2019
8.39
-0.48
-5.41%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 25 in the most recent period (2026/Q3).
- Total institutional ownership fell 3.1 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 87.04% -3.06pp
- Institutions
- 317 +25
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund47.33%
VC/PE Fund19.92%
Hedge Fund13.43%
Individual/Insider4.23%
Public Company3.35%
Private Company0.97%
Insurance Company0.92%
Government Pension Fund0.77%
Endowment Fund0.23%
Other8.84%
Top holders as of 2026-09-30
BlackRock
12.21% · 20.91M sh
Vanguard Portfolio Management, LLC
7.02% · 12.02M sh
Arch Venture Partners, L.P.
6.95% · 11.90M sh
SB Investment Advisers (UK) Limited
6.39% · 10.95M sh
GSK Equity Investments, Limited
4.99% · 8.55M sh
State Street Global Advisors
4.57% · 7.82M sh
Vanguard Capital Management, LLC
3.77% · 6.45M sh
Point72 Asset Management, L.P.
3.31% · 5.67M sh
George Scangos
2.21% · 3.78M sh
Dimensional Fund Advisors
1.94% · 3.32M sh
Geode Capital Management, LLC
1.98% · 3.35M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 20 buys · 27 sells
| Name | Role | Stake |
|---|---|---|
| George Scangos | Former Director | 2.21% |
| Vicki Sato | Independent Chairperson | 0.62% |
| Marianne De Backer | Chief Executive Officer | 0.58% |
| Robert Taylor Nelsen | Former Independent Director | 0.36% |
| Vanina de Verneuil | General Counsel | 0.06% |
| Ann Hanly | Former Executive VP & Chief Technology Officer | 0.04% |
| Brent Sabatini | Senior VP, Principal Accounting Officer & Chief Accounting Officer | 0.04% |
| Robert J. More | Independent Director | 0.02% |
| Charles Sigal | Independent Director | 0.01% |
| Jason O'Byrne | -- | 0.01% |
| Jeffrey Hatfield | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-02 | Vanina de Verneuil | General Counsel | Open Market Disposition | -3,750 | $11.10–11.33 |
| 2026-11-02 | Vanina de Verneuil | General Counsel | Intent to Sell (Form 144) | -2,407 | $11.10 |
| 2026-11-01 | Vanina de Verneuil | General Counsel | Intent to Sell (Form 144) | -1,343 | $11.33 |
| 2026-10-26 | Suzanne Topalian | Director | Other Acquisition | +12,731 | -- |
| 2026-10-26 | Suzanne Topalian | Director | Other Derivative Acquisition | +25,462 | $11.57 |
| 2026-10-26 | Suzanne Topalian | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-10-04 | Aziz Sawaf | Executive VP, CFO & Principal Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-16 | Jason O'Byrne | -- | Intent to Sell (Form 144) | -19,357 | $11.00 |
| 2026-09-08 | Jason O'Byrne | -- | Intent to Sell (Form 144) | -28,333 | $11.13 |
| 2026-08-24 | Jason O'Byrne | -- | Intent to Sell (Form 144) | -23,148 | $10.48 |
| 2026-08-23 | Jason O'Byrne | -- | Intent to Sell (Form 144) | -14,352 | $9.90 |
| 2026-08-20 | Jason O'Byrne | -- | Intent to Sell (Form 144) | -25,000 | $9.81 |
| 2026-08-10 | Alta Partners LP | -- | Other Acquisition | +8,000 | -- |
| 2026-08-10 | Robert J. More | Independent Director | Other Disposition | -8,000 | -- |
| 2026-06-28 | Sona Saira Ramasastry | Former Independent Director | Intent to Sell (Form 144) | -16,000 | $10.32 |
| 2026-06-08 | Timothy Coughlin | Director | Other Acquisition | +16,000 | -- |
| 2026-06-08 | Timothy Coughlin | Director | Other Derivative Acquisition | +16,000 | $8.51 |
| 2026-06-08 | Timothy Coughlin | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-05-31 | Janet Napolitano | Independent Director | Automatic Disposition | -3,200 | $9.45 |
| 2026-05-31 | Brent Sabatini | Senior VP, Principal Accounting Officer & Chief Accounting Officer | Automatic Disposition | -379 | $9.45 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Vir Biotechnology discussion 0 comments